A new long-acting analogue based on liquid crystal technology, CAM2029, was shown by Diego Ferone and coauthors to be highly effective, and indicating that self- or partner-injection can be used, as for lanreotide autogel. That study, Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1 published in May
Reported effects include nausea, facial flushing, skin reactions, and pigment changes, among others
You can gradually escalate your physical activity
Active Ingredients & Benefits: Glutathione: Antioxidant that reduces pigmentation and brightens skin
After the patent issue, he tried to interest when large diabetes drug company, but all the company rejected his opportunity
doi: 10.1098/rstb.2017.0230